X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Dishman Pharma with ASTRAZENECA PHARMA - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DISHMAN PHARMA vs ASTRAZENECA PHARMA - Comparison Results

DISHMAN PHARMA    Change

Dishman Pharmaceuticals is involved in the manufacture of APIs (active pharmaceutical ingredients), intermediates, quaternary compounds and fine chemicals. Besides this, the company is a significant player in the CRAMS (Contract Research and Manufact... More

ASTRAZENECA PHARMA 
   Change

AstraZeneca Pharma India Limited (APIL) is a 90% subsidiary of the UK based AstraZeneca Pharmaceuticals, which is one of the world's leading pharma companies. APIL has interests in the six crucial areas of cardiovascular, respiratory, maternal health... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DISHMAN PHARMA ASTRAZENECA PHARMA DISHMAN PHARMA/
ASTRAZENECA PHARMA
 
P/E (TTM) x 25.1 104.7 24.0% View Chart
P/BV x 3.3 14.9 22.4% View Chart
Dividend Yield % 0.7 0.0 -  

Financials

 DISHMAN PHARMA   ASTRAZENECA PHARMA
EQUITY SHARE DATA
    DISHMAN PHARMA
Mar-16
ASTRAZENECA PHARMA
Mar-14
DISHMAN PHARMA/
ASTRAZENECA PHARMA
5-Yr Chart
Click to enlarge
High Rs3741,285 29.1%   
Low Rs129634 20.3%   
Sales per share (Unadj.) Rs197.8189.6 104.3%  
Earnings per share (Unadj.) Rs21.2-0.2 -10,415.4%  
Cash flow per share (Unadj.) Rs34.73.8 903.2%  
Dividends per share (Unadj.) Rs2.000-  
Dividend yield (eoy) %0.80-  
Book value per share (Unadj.) Rs179.968.6 262.1%  
Shares outstanding (eoy) m80.6925.00 322.8%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x1.35.1 25.1%   
Avg P/E ratio x11.9-4,712.7 -0.3%  
P/CF ratio (eoy) x7.2249.6 2.9%  
Price / Book Value ratio x1.414.0 10.0%  
Dividend payout %9.40-   
Avg Mkt Cap Rs m20,30623,988 84.7%   
No. of employees `0000.81.6 53.2%   
Total wages/salary Rs m5,3551,605 333.7%   
Avg. sales/employee Rs Th19,252.73,040.2 633.3%   
Avg. wages/employee Rs Th6,459.51,029.2 627.6%   
Avg. net profit/employee Rs Th2,064.1-3.3 -63,219.2%   
INCOME DATA
Net Sales Rs m15,9614,740 336.7%  
Other income Rs m26592 288.2%   
Total revenues Rs m16,2264,832 335.8%   
Gross profit Rs m4,103-130 -3,161.2%  
Depreciation Rs m1,091101 1,077.7%   
Interest Rs m9440-   
Profit before tax Rs m2,334-139 -1,680.1%   
Minority Interest Rs m00-   
Prior Period Items Rs m10-   
Extraordinary Inc (Exp) Rs m0139 0.0%   
Tax Rs m6245 12,251.5%   
Profit after tax Rs m1,711-5 -33,616.9%  
Gross profit margin %25.7-2.7 -938.8%  
Effective tax rate %26.7-3.7 -729.2%   
Net profit margin %10.7-0.1 -9,983.0%  
BALANCE SHEET DATA
Current assets Rs m11,0182,726 404.1%   
Current liabilities Rs m9,5172,435 390.8%   
Net working cap to sales %9.46.1 153.0%  
Current ratio x1.21.1 103.4%  
Inventory Days Days11074 149.8%  
Debtors Days Days3541 85.5%  
Net fixed assets Rs m16,3041,035 1,574.8%   
Share capital Rs m16150 322.8%   
"Free" reserves Rs m12,907942 1,369.6%   
Net worth Rs m14,5161,716 845.9%   
Long term debt Rs m4,1890-   
Total assets Rs m29,8054,156 717.2%  
Interest coverage x3.5NM-  
Debt to equity ratio x0.30-  
Sales to assets ratio x0.51.1 47.0%   
Return on assets %8.9-0.1 -7,274.7%  
Return on equity %11.8-0.3 -3,974.1%  
Return on capital %17.50-  
Exports to sales %24.85.7 434.8%   
Imports to sales %3.76.5 57.8%   
Exports (fob) Rs m3,956270 1,464.2%   
Imports (cif) Rs m596306 194.7%   
Fx inflow Rs m4,952375 1,321.8%   
Fx outflow Rs m697470 148.2%   
Net fx Rs m4,255-96 -4,452.9%   
CASH FLOW
From Operations Rs m2,786-8 -34,400.0%  
From Investments Rs m-1,529-146 1,049.3%  
From Financial Activity Rs m-941862 -109.2%  
Net Cashflow Rs m316709 44.7%  

Share Holding

Indian Promoters % 61.4 0.0 -  
Foreign collaborators % 0.0 75.0 -  
Indian inst/Mut Fund % 3.7 0.3 1,233.3%  
FIIs % 12.7 15.7 80.9%  
ADR/GDR % 0.0 0.0 -  
Free float % 22.1 9.1 242.9%  
Shareholders   46,261 12,856 359.8%  
Pledged promoter(s) holding % 35.8 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DISHMAN PHARMA With:   FRESENIUS KABI ONCO.  AJANTA PHARMA  UNICHEM LAB  ALEMBIC PHARMA  CADILA HEALTHCARE  

Compare DISHMAN PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Finishes Marginally Lower; Capital Goods & Realty Stocks Fall(Closing)

Indian share markets witnessed selling pressure in the final hour of trade to finish just below the dotted line. At the closing bell, the BSE Sensex closed lower by 71 points.

Related Views on News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

Follow India's Super Investors to Make Big Money in the Market Crash(The 5 Minute Wrapup)

Feb 8, 2018

Has the sell-off in the markets left India's super investors unduly worried?

The Era of Easy Money is Coming to an End. What Happens Now?(Vivek Kaul's Diary)

Feb 9, 2018

The easy money policy of the Federal Reserve of the United States, which drove up stock markets all over the world, is ending, with the Federal Reserve looking to shrink its balance sheet.

The Markets Want Your Money. Don't Give It to Them.(Smart Contrarian)

Feb 9, 2018

MFs are having a gala time taking money from over-eager investors and funneling it into equities. Smart investors, though, know better than to do that.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

Rising Dominance of Mutual Funds(Chart Of The Day)

Feb 8, 2018

Domestic money flow into Indian equities surpassed foreign fund flows in the recent years. But will it continue in volatile market?

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

DISHMAN PHARMA SHARE PRICE


May 29, 2017 (Close)

TRACK DISHMAN PHARMA

  • Track your investment in DISHMAN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON DISHMAN PHARMA

DISHMAN PHARMA 8-QTR ANALYSIS

COMPARE DISHMAN PHARMA WITH

MARKET STATS